2025年Q1司美格鲁肽以84.1亿美元登顶药王,7.2mg新剂量欧洲申请获批在即;新一代减重药全球进度领先。诺和诺德多维进击,寸步不让,持续加码代谢领域。01全球药王司美格鲁肽2024年,司美格鲁肽以约292.96亿美元的全球收入奠定了GLP-1RA药物市场基石;2025年Q1,其销售额再攀高峰至84.1亿美元,同比增长32%,正式超越默沙东的K药(72.05亿美元),2025年成为全球新一代“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.